Vera Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Vera Therapeutics, Inc. filed a current report on December 14, 2021, regarding an event occurring on December 10, 2021. The filing reports the appointment of Kimball Hall to the company’s board of directors.
Board Appointment and Compensation
- Kimball Hall was appointed effective December 10, 2021, as a Class I director.
- Her initial term expires at the company’s 2022 Annual Meeting of Stockholders.
- She received an option to purchase 19,850 shares of Class A common stock, vesting monthly over three years, subject to continued service.
- She will receive an annual cash retainer of $35,000 for board service, prorated for 2021.
- Beginning with the 2022 Annual Meeting, she will be eligible for annual options to purchase 9,925 shares. Each grant vests on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service.
- Ms. Hall entered into the company’s standard indemnification agreement.
Financial Metrics and Material Changes
This filing does not provide revenue, earnings, cash flow, margin, debt, liquidity, or other operating performance metrics. It does not report a material change in financial results versus a comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. It states that there were no arrangements or understandings with other persons relating to Ms. Hall’s selection and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the terms, exercise price, accounting valuation, and dilution impact of the 19,850-share initial stock option.
- Review future annual director option grants and related equity compensation expense.
- Confirm Ms. Hall’s election at the 2022 Annual Meeting and the applicable board compensation policy.
- Review subsequent filings for changes to board composition, director compensation, or equity awards.